|Articles|March 14, 2022

New “Deltacron” COVID-19 Sub-Variant Could Be as Contagious as Measles

Author(s)Nina Cosdon

The new COVID-19 sub-variant, called “Deltacron” or “Stealth Omicron,” appears to be the most contagious strain yet. However, this does not necessarily mean there will be a dramatic spike in cases.

The new Deltacron COVID-19 variant does not initially appear to be any more severe than Omicron, but it is more transmissible.

The new COVID-19 sub-variant of the Delta and Omicron strains has been circulating since the beginning of the year. “Deltacron,” is a recombinant virus that contains the full-length spike protein of Omicron and the backbone of Delta.

Dr. Adrian Esterman, a professor at the University of South Australia and former World Health Organization (WHO) epidemiologist, tweeted that Deltacron is approximately 1.4 times more infectious than the original Omicron strain BA.1. “This makes it pretty close to measles, the most contagious disease we know about,” Esterman wrote.

The basic reproduction number for BA.1 is about 8.2, and is nearly 12 for BA.2. The most recent updates estimate Deltacron accounts for 57% of cases in England. In the US, the Centers for Disease Control and Prevention (CDC) estimate BA.2 increased from 1% of cases in early February to 11% by early March.

The sub-variant has been identified in the US, the UK, the Netherlands, Denmark, and France, and it has likely spread farther. However, experts are not predicting a dramatic surge of infections. Case numbers are falling, and continue to do so even as BA.2 slowly becomes more prevalent in the US.

The sub-variant is also nicknamed the “stealth variant” or “stealth Omicron,” due to its ability to be nearly indistinguishable from Delta or Omicron in positive PCR tests.

The Omicron BA.1 variant caused an unprecedented number of breakthrough infections in vaccinated individuals, but COVID-19 vaccines remained highly effective against hospitalization and death. British health officials reported the BA.1 and BA.2 variants are similarly susceptible to vaccination, especially with a booster shot.

Like Omicron, Deltacron can evade monoclonal antibody treatment. Other approved treatments, like Paxlovid, molnupiravir, and remdesivir, remain effective if initiated shortly after COVID-19 diagnosis.

Recombinant viruses are fairly common, they occur when 1 variant overtakes the previously dominant strain and the same host cell is co-infected by these 2 distinct viruses. Due to the prevalence of the Delta and Omicron variants, health officials expected COVID-19 to mutate into a recombinant virus.

So far, the WHO has not dubbed BA.2 a variant of concern.


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.